Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 22 of the 45 sources its claims cite were checked for support.

Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials

Open access

Abstract

BACKGROUND: In 2019, the FDA and EMA approved intranasal esketamine for treatment-resistant depression (TRD). The current study re-evaluated its efficacy and safety. METHODS: This registered report presents a systematic review and individual patient data (IPD) meta-analysis of double-blind, randomised, placebo-controlled trials (RCTs) assessing intranasal esketamine for TRD. Two reviewers independently screened studies from multiple databases and obtained IPD via the Yale Open Data Access Project. Two independent researchers selected studies and assessed risk of bias. The primary outcome was the Montgomery-Åsberg Depression Rating Scale (MADRS) score at ≥ 4 weeks in initiation trials, benchmarked against the 6.5-point clinical significance threshold used in the design of pivotal trials. Evidence certainty was rated using GRADE. Secondary outcomes included additional efficacy and safety endpoints. A two-step IPD meta-analysis was conducted, with separate analyses by trial phase (initiation vs. continuation) and treatment type (combination vs. monotherapy). A one-stage meta-analysis explored moderators (e.g. age and resistance level). RESULTS: We re-analysed IPD from 7 RCTs including 1505 patients. In five initiation trials of esketamine plus an antidepressant, esketamine reduced MADRS scores at 4 weeks (mean difference (MD) = - 2.94, 95% CI [- 5.39 to - 0.48]; GRADE: moderate certainty). A continuation trial showed reduced relapse risk (HR = 0.38 [0.26-0.57]), though FDA concerns about one centre could not be addressed due to data privacy restrictions. A monotherapy trial (aggregate data only) showed a larger effect (MD = - 6.32 [- 8.62 to - 4.03]), but there were concerns over selection bias and unblinding. Esketamine increased sedation (RR = 3.70 [2.02-6.78]), dissociation (RR = 2.36 [2.10-2.65]), and adverse events (IRR = 3.91 [2.37-6.45]), with no increase in serious adverse events (IRR = 1.35 [0.54-3.40]). No treatment effect moderation was found by age or resistance level, with most patients displaying low-stage TRD. CONCLUSIONS: Based on the IPD used for approval, esketamine in combination with an antidepressant showed an advantage over placebo that was statistically significant but small. The clinical relevance of this benefit is unclear, particularly given the risks of adverse events. STUDY REGISTRATION: PROSPERO: CRD42021290721.

Overview

CoChat Summary

TL;DR

In this individual patient data meta-analysis of 7 placebo-controlled esketamine trials including 1505 patients, esketamine plus an antidepressant produced a statistically significant but small MADRS reduction at 4 weeks (MD −2.94) that fell below the trials’ prespecified 6.5-point clinical significance threshold. Esketamine increased adverse events, dissociation, and sedation without increasing serious adverse events, and no efficacy moderation by age or resistance stage was found.

Key findings

  • In five initiation trials of esketamine plus an antidepressant, esketamine reduced MADRS scores at ≥4 weeks versus placebo (MD = −2.94, 95% CI [−5.39 to −0.48]; GRADE moderate certainty), but the entire confidence interval failed to meet the prespecified −6.5-point threshold; the effect corresponded to SMD −0.25 (95% CI −0.45 to −0.06).
  • In the continuation trial, esketamine reduced relapse risk (HR = 0.38 [0.26–0.57]), but FDA concerns about one centre could not be addressed due to data privacy restrictions; excluding all Polish centres reduced the primary remission effect and made it non-significant.
  • A monotherapy trial using aggregate data only showed a larger effect (MD = −6.32 [−8.62 to −4.03]), but the paper reports concerns over selection bias and functional unblinding.
  • Esketamine increased sedation (RR = 3.70 [2.02–6.78]), dissociation (RR = 2.36 [2.10–2.65]), and adverse events (IRR = 3.91 [2.37–6.45]), with no increase in serious adverse events (IRR = 1.35 [0.54–3.40]); no treatment effect moderation was found by age or resistance level, and most patients had low-stage TRD.

Methods

  • Systematic review and individual patient data meta-analysis of double-blind, randomised, placebo-controlled trials of intranasal esketamine for treatment-resistant depression; registered on PROSPERO (CRD42021290721), reported per PRISMA and PRISMA-IPD, with IPD obtained via the Yale Open Data Access Project.
  • Two-step IPD meta-analysis conducted separately by trial phase (initiation vs. continuation) and treatment type (combination vs. monotherapy); primary outcome was MADRS score at ≥4 weeks, benchmarked against the 6.5-point clinical significance threshold used in pivotal trials; one-stage meta-analysis explored moderators including age and resistance level; GRADE assessed certainty.
  • Data included 7 RCTs with 1505 randomised participants: six initiation studies (one 1-week, five 4-week) and one continuation study; one monotherapy RCT (476 participants) was analysed separately from aggregate data because IPD were unavailable.

Limitations

  • The paper states that centre information was missing from the IPD due to anonymisation, so the FDA concern about a specific centre in Poland could not be directly investigated; the country-based analysis was considered weak and exploratory.
  • The paper states that two initiation trials showed unexpected data patterns before and after interim analysis, indicating potential bias, and that functional unblinding was likely because no formal assessment of unblinding was conducted in pivotal RCTs.
  • The paper states that prior ECT use was not systematically assessed, reconstructing several variables and resistance stage introduced methodological variability, few patients had high resistance limiting subgroup power, and too few studies were available for a funnel plot.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12916-025-04435-x

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Flow diagram. *NCT02133001, NCT03039192 and NCT03097133 were not limited to treatment-resistant depression (TRD) and provided insufficient information regarding prior resistance in the individual patient data (IPD); NCT03185819 and NCT02919579 were not limited to treatment-resistant depression (TRD) and did not provided IPD. **NCT03852160 has stopped before enrolling its first participant; ChiCTR2000038915 has not responded to our request to share data
Fig. 1 Flow diagram. *NCT02133001, NCT03039192 and NCT03097133 were not limited to treatment-resistant depression (TRD) and provided insufficient information regarding prior resistance in the individual patient data (IPD); NCT03185819 and NCT02919579 were not limited to treatment-resistant depression (TRD) and did not provided IPD. **NCT03852160 has stopped before enrolling its first participant; ChiCTR2000038915 has not responded to our request to share dataCC BY-NC-ND · PubMed Central
Fig. 2 Results of re-analyses compared to those reported in published papers. Point estimates in green represent studies where the main results were considered to achieve inferential reproducibility. In contrast, point estimates in red indicate analyses where inferential reproducibility was not achieved, either due to reporting bias in NCT01998958 or failure to adhere to the hierarchical analysis in NCT02417064
Fig. 2 Results of re-analyses compared to those reported in published papers. Point estimates in green represent studies where the main results were considered to achieve inferential reproducibility. In contrast, point estimates in red indicate analyses where inferential reproducibility was not achieved, either due to reporting bias in NCT01998958 or failure to adhere to the hierarchical analysis in NCT02417064CC BY-NC-ND · PubMed Central
Fig. 3 Hierarchical analysis details in NCT02417064—data integrity checks
Fig. 3 Hierarchical analysis details in NCT02417064—data integrity checksCC BY-NC-ND · PubMed Central
Fig. 4 Leave-one-out analysis of NCT02493868 at the country level—data integrity checks. The figure shows the overall effect when each country is excluded, not results by individual country
Fig. 4 Leave-one-out analysis of NCT02493868 at the country level—data integrity checks. The figure shows the overall effect when each country is excluded, not results by individual countryCC BY-NC-ND · PubMed Central
Fig. 5 Forest plot and risk of bias (RoB2) assessment for MADRS at 4 weeks in initiation trials (in combination A, and monotherapy B) and relapse in continuation trial (combination study C). A and C are based on IPD. B is based on aggregated data. Dashed lines represent the lower and upper prespecified thresholds (± 6.5 points) and the null effect (0). Green-shaded areas denote effects exceeding the threshold, while the red-shaded area indicates effects below the threshold. CI: confidence interval, SD: standard deviation, Rel: relapsed, Cens: censored, R: bias arising from the randomisation process, D: bias due to deviations from intended interventions, Mi: bias due to missing outcome data, Me: bias in measurement of the outcome, S: bias in selection of the reported results, O: overall risk of bias
Fig. 5 Forest plot and risk of bias (RoB2) assessment for MADRS at 4 weeks in initiation trials (in combination A, and monotherapy B) and relapse in continuation trial (combination study C). A and C are based on IPD. B is based on aggregated data. Dashed lines represent the lower and upper prespecified thresholds (± 6.5 points) and the null effect (0). Green-shaded areas denote effects exceeding the threshold, while the red-shaded area indicates effects below the threshold. CI: confidence interval, SD: standard deviation, Rel: relapsed, Cens: censored, R: bias arising from the randomisation process, D: bias due to deviations from intended interventions, Mi: bias due to missing outcome data, Me: bias in measurement of the outcome, S: bias in selection of the reported results, O: overall risk of biasCC BY-NC-ND · PubMed Central
Fig. 6 Distribution of modified observer assessment of alertness and sedation (MOAAS) scores across trials. The categories of the MOAAS scale are as follows: (5) responds readily to name spoken in normal tone, (4) lethargic response to name spoken in normal tone, (3) responds only after name is called loudly and/or repeatedly, (2) responds only after mild prodding or shaking, (1) responds only after painful trapezius squeeze, (0) does not respond to painful trapezius squeeze
Fig. 6 Distribution of modified observer assessment of alertness and sedation (MOAAS) scores across trials. The categories of the MOAAS scale are as follows: (5) responds readily to name spoken in normal tone, (4) lethargic response to name spoken in normal tone, (3) responds only after name is called loudly and/or repeatedly, (2) responds only after mild prodding or shaking, (1) responds only after painful trapezius squeeze, (0) does not respond to painful trapezius squeezeCC BY-NC-ND · PubMed Central
Fig. 7 Subgroup analyses exploring moderators of esketamine efficacy. For age, differences in means are presented by age class for visualization purposes. However, the analysis corresponds to a test where age is used as a continuous variable, as pre-specified
Fig. 7 Subgroup analyses exploring moderators of esketamine efficacy. For age, differences in means are presented by age class for visualization purposes. However, the analysis corresponds to a test where age is used as a continuous variable, as pre-specifiedCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

16 Valid · 0 Not valid · 19 Not checked · 70 Own results and interpretations

67 more claims · 3 with their cited sources checked

Create a free account to see all 105 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 25
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 37 references

Research works printed but not linked: 2

  1. Lan CH, Wei JC. Esketamine nasal spray versus quetiapine for resistant depression. N Engl J Med. 2024;390(1):93–4. · DOI · Paper page
  2. Pharmacoeconomic report: esketamine hydrochloride (Spravato): (Janssen Inc.): indication: major depressive disorder in adults. Ontario, Canada; 2021. https://www.ncbi.nlm.nih.gov/books/NBK572204/.

Cited by

See all 6

Metadata

Authors
Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A.
Affiliations
  • Inserm (FR)
  • Babeș-Bolyai University (RO)
  • University of Verona (IT)
  • Oregon Health & Science University (US)
  • University of Padua (IT)
Corresponding author
Naudet, Florian
Venue
BMC Medicine
Published
2025-11-28
Volume
23
Issue
1
Pages
677-677
ISSN
1741-7015 (ISSN-L)
OpenAlex
W4416769789
Cited by
6
References
37
Citations by year
2026: 6
FWCI
0.81
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
direction de l’hospitalisation et de l’offre de soins (ESK-T-Dep)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
esketamine, treatment-resistant depression, intranasal administration, antidepressant monotherapy, combination therapy, relapse prevention, sedation, dissociation, adverse events, treatment efficacy, risk of bias, age and treatment response, resistance levels
MeSH terms
Pre-Registration Publication, Administration, Intranasal, Antidepressive Agents, Double-Blind Method, Humans, Ketamine, Randomized Controlled Trials as Topic, Treatment Outcome, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials. https://app.cochat.ai/papers/10.1186/s12916-025-04435-x
The paper
Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025). Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials. BMC Medicine. https://doi.org/10.1186/s12916-025-04435-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.